Investing

Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale

Moderna Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale decreased by 21.2% to $732.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 62.1%, from $1.93B to $732.00M. Over 4 years (FY 2021 to FY 2025), Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale shows an upward trend with a 42.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementCash Flow Statement
SectionInvesting
CategoryLiquidity
SignalHigher is better
VolatilityModerate
First reportedQ1 2016
Last reportedQ1 2026May 1, 2026

How to read this metric

Higher values indicate a high volume of maturing debt, providing liquidity for reinvestment or capital return.

Detailed definition

Cash inflows generated when debt securities held in the investment portfolio reach their maturity date, are called by th...

Peer comparison

Standard for insurance companies with large fixed-income portfolios to match long-term liabilities.

Metric ID: investing_proceeds_from_maturities_prepayments_and_calls_bc784f

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$521.00M$215.00M$263.00M$441.00M$968.00M$813.00M$929.00M$1.36B$1.90B$1.45B$864.00M$1.57B$1.96B$1.11B$914.00M$1.93B$1.49B$1.21B$929.00M$732.00M
QoQ Change-58.7%+22.3%+67.7%+119.5%-16.0%+14.3%+46.4%+40.0%-24.0%-40.3%+82.1%+24.8%-43.4%-17.8%+111.5%-22.9%-18.8%-23.2%-21.2%
YoY Change+85.8%+278.1%+253.2%+208.4%+96.7%+78.0%-7.0%+15.7%+3.1%-23.2%+5.8%+22.9%-24.0%+8.8%+1.6%-62.1%
Range$215.00M$1.96B
CAGR+7.4%
Avg YoY Growth+58.9%
Median YoY Growth+12.2%
Current Streak4 quarters decline

Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at Other Companies

Frequently Asked Questions

What is Moderna's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
Moderna (MRNA) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $732.00M in Q1 2026.
How has Moderna's proceeds from maturities, prepayments and calls of debt securities, available-for-sale changed year-over-year?
Moderna's proceeds from maturities, prepayments and calls of debt securities, available-for-sale decreased by 62.1% year-over-year, from $1.93B to $732.00M.
What is the long-term trend for Moderna's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
Over 4 years (2021 to 2025), Moderna's proceeds from maturities, prepayments and calls of debt securities, available-for-sale has grown at a 42.8% compound annual growth rate (CAGR), from $1.34B to $5.56B.
What does proceeds from maturities, prepayments and calls of debt securities, available-for-sale mean?
Cash received from debt investments that have matured or been called.